Group 1 - The performance of the Beijing Stock Exchange (BSE) in Q1-Q3 2025 shows a recovery in revenue but pressure on profitability, with total revenue of 145.1 billion yuan, a year-on-year increase of 6%, and net profit of 9.2 billion yuan, a year-on-year decrease of 7% [1][6][10] - Leading companies and scarce assets are outperforming, with notable performances from companies like Jinbo Biological, Betterray, and Development Technology, which have shown strong growth [1][30] - The industry shows significant differentiation, with the highest revenue growth in beauty care (+30%), petroleum and petrochemicals (+24%), communication (+18%), and automotive (+17%), while most industries face challenges of revenue growth with profitability under pressure [1][18][19] Group 2 - A total of 19 companies reported a net profit greater than 100 million yuan with positive growth, indicating strong performance among leading firms [1][36] - There are 23 companies identified as long-term high achievers, with a compound annual growth rate (CAGR) of over 15% from 2022 to 2024, and revenue growth exceeding 10% in Q1-Q3 2025, including Jinbo Biological and Kaiter Co [1][38] - The BSE 50 index has shown resilience, with a median net profit of 460 million yuan, surpassing that of the Sci-Tech Innovation Board, reflecting a competitive advantage in profitability [1][24][25]
2025Q1-Q3北证业绩稳中趋暖，加快推出北证50ETF增量资金可期：北交所周观察第五十期（20251102）
Hua Yuan Zheng Quan·2025-11-02 11:28